Roman Maslennikov
Overview
Explore the profile of Roman Maslennikov including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
290
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
31.
Maslennikov R, Ivashkin V, Vasilieva E, Chipurik M, Semikova P, Semenets V, et al.
Eur Cytokine Netw
. 2021 Aug;
32(1):8-14.
PMID: 34346869
Cytokine release syndrome is a serious complication of the new coronavirus infection (COVID-19). The aim of the study was to assess effectiveness and safety of the IL-17 antagonist nekatimab for...
32.
Maslennikov R, Ivashkin V, Efremova I, Alieva A, Kashuh E, Tsvetaeva E, et al.
World J Hepatol
. 2021 Jun;
13(5):557-570.
PMID: 34131470
Background: Gut dysbiosis is common in cirrhosis. Aim: To study the influence of gut dysbiosis on prognosis in cirrhosis. Methods: The case-control study included 48 in-patients with cirrhosis and 21...
33.
Maslennikov R, Ivashkin V, Efremova I, Shirokova E
World J Gastroenterol
. 2021 May;
27(18):2073-2089.
PMID: 34025065
Infection with hepatotropic viruses is not limited to the liver and can lead to the development of various immunological disorders (the formation of cryoglobulins, rheumatoid factor, antinuclear antibodies, autoantibodies specific...
34.
Maslennikov R, Ivashkin V, Vasilieva E, Chipurik M, Semikova P, Semenets V, et al.
Pulm Pharmacol Ther
. 2021 May;
69:102039.
PMID: 34023513
Background And Aim: Cytokine release syndrome is a dangerous complication of the coronavirus disease 2019 (COVID-19). This study aimed to evaluate the efficacy and safety of tofacitinib in the management...
35.
Maslennikov R, Ivashkin V, Ufimtseva A, Poluektova E
Minerva Gastroenterol (Torino)
. 2021 Apr;
68(4):487-489.
PMID: 33856143
No abstract available.
36.
Maslennikov R, Poluektova E, Ivashkin V, Svistunov A
Infect Dis (Lond)
. 2021 Feb;
53(5):348-360.
PMID: 33583306
Aim: Diarrhoea is a relatively common manifestation of coronavirus disease (COVID-19), but there is no systematic review which comprehensively describes it beyond its incidence and impact on prognosis. This study...
37.
Maslennikov R, Pavlov C, Ivashkin V
Turk J Gastroenterol
. 2019 Nov;
30(11):964-975.
PMID: 31767551
Background/aims: Small intestinal bacterial overgrowth (SIBO) and hemodynamic changes are common in cirrhosis. We wanted to examine our hypothesis whether SIBO leads to hemodynamic changes in cirrhosis. Materials And Methods:...
38.
Maslennikov R, Driga A, Ivashkin K, Ivashkin V
Gastroenterol Hepatol Bed Bench
. 2018 Nov;
11(4):325-332.
PMID: 30425812
Aim: To assess NT-proBNP as a biomarker for hyperdynamic circulation in decompensated cirrhosis. Background: Hyperdynamic circulation is common in decompensated cirrhosis. The previous studies reveal that N-terminal-proBNP (NT-proBNP) is elevated...
39.
Maslennikov R, Pavlov C, Ivashkin V
Hepatol Int
. 2018 Oct;
12(6):567-576.
PMID: 30284684
Background: Small intestinal bacterial overgrowth (SIBO) was detected in cirrhosis in many studies. The aim is to perform a systematic review and meta-analysis on the prevalence of SIBO in cirrhosis...